NICE Clears Verzenios For Breast Cancer After Lilly Offers UK Discount
Executive Summary
Verzenios, Lilly’s new drug for metastatic breast cancer, has been OKd by NICE for use on the national health service in England and Wales. In terms of gaining market share it is some way behind two other competitor drugs, Pfizer’s Ibrance and Novartis’s Kisqali, but it has some clinical advantages that could allow it to gain uptake.
You may also be interested in...
Lilly Scores New Treatment Option For Verzenios In England
Health technology assessment body NICE says that Verzenios when used with fulvestrant can be used to treat advanced breast cancer via the Cancer Drugs Fund, giving Eli Lilly the edge in this space for now over rival CDK4/6 manufacturers, Pfizer and Novartis.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.